OmniAbOABI
OABI
About: OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Employees: 106
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
66% more call options, than puts
Call options by funds: $163K | Put options by funds: $98K
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
13% more capital invested
Capital invested by funds: $295M [Q2] → $334M (+$39.3M) [Q3]
3% more funds holding
Funds holding: 159 [Q2] → 163 (+4) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0.01% less ownership
Funds ownership: 67.54% [Q2] → 67.53% (-0.01%) [Q3]
4% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 45
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
129%
upside
Avg. target
$9.50
171%
upside
High target
$11
214%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Benchmark Robert Wasserman 55% 1-year accuracy 27 / 49 met price target | 129%upside $8 | Buy Reiterated | 14 Nov 2024 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 79 / 384 met price target | 214%upside $11 | Buy Reiterated | 14 Nov 2024 |
Financial journalist opinion
Neutral
Business Wire
5 days ago
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from tradition.
Neutral
Seeking Alpha
1 month ago
OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Alex Xenakis - Truist Securities Jacqueline Kisa - TD Cowen Conor McNamara - RBC Capital Markets Operator Good afternoon, and welcome to OmniAb, Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago.
Neutral
Business Wire
1 month ago
OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. “We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives an.
Neutral
Business Wire
1 month ago
OmniAb to Participate in Two Investor Conferences in November
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of November. Stifel 2024 Healthcare Conference, November 18-19 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Tuesday, November 19th. Jefferies London Healthcare Conference, November 19-21 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer.
Neutral
Business Wire
1 month ago
OmniAb to Report Third Quarter 2024 Financial Results on November 12
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter financial results and business updates Date: Tuesday, November 12, 2024 Time: .
Neutral
Business Wire
3 months ago
OmniAb to Participate in Two Investor Conferences in September
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of September. H.C. Wainwright 26th Annual Global Investment Conference, September 9-11 at the Lotte New York Palace Hotel. Management will deliver a corporate presentation on Tuesday, September 10th at 2:30 p.m. Eastern Time and will hold one-on-one meetings with investors. Craig-Hallum Bioprocessing Virtual Conference, September 19t.
Neutral
Seeking Alpha
4 months ago
OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporated 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Neutral
Business Wire
4 months ago
OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. “Second quarter results were in-line with our expectations and support our view of the full year. We advanced our business by adding new partnerships and programs as existing partners made important clinical progress in their respective programs,” said Matt Foehr, Chief Executive Officer of OmniAb.
Positive
Seeking Alpha
4 months ago
Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 2000 remains a more appropriate benchmark for comparison. Top gainers include FTAI Aviation and FTAI Infrastructure, while top detractors include Latch and Industrial Short.
Charts implemented using Lightweight Charts™